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Research Article
KLB, encoding b-Klotho, is mutated in patients with
congenital hypogonadotropic hypogonadism
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Nicolas J Niederländer1, Justine Bouilly1, Andrew A Dwyer1,3, Yisrael Sidis1, Daniele Cassatella1,
Gerasimos P Sykiotis1, Richard Quinton4, Christian De Geyter5, Mirjam Dirlewanger6,
Valérie Schwitzgebel6, Trevor R Cole7, Andrew A Toogood8, Jeremy MW Kirk9, Lacey Plummer10,
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Abstract
Congenital hypogonadotropic hypogonadism (CHH) is a rare
genetic form of isolated gonadotropin-releasing hormone (GnRH)
deficiency caused by mutations in > 30 genes. Fibroblast growth
factor receptor 1 (FGFR1) is the most frequently mutated gene in
CHH and is implicated in GnRH neuron development and mainte-
nance. We note that a CHH FGFR1 mutation (p.L342S) decreases
signaling of the metabolic regulator FGF21 by impairing the associ-
ation of FGFR1 with b-Klotho (KLB), the obligate co-receptor for
FGF21. We thus hypothesized that the metabolic FGF21/KLB/FGFR1
pathway is involved in CHH. Genetic screening of 334 CHH patients
identified seven heterozygous loss-of-function KLB mutations in 13
patients (4%). Most patients with KLB mutations (9/13) exhibited
metabolic defects. In mice, lack of Klb led to delayed puberty,
altered estrous cyclicity, and subfertility due to a hypothalamic
defect associated with inability of GnRH neurons to release GnRH
in response to FGF21. Peripheral FGF21 administration could
indeed reach GnRH neurons through circumventricular organs in
the hypothalamus. We conclude that FGF21/KLB/FGFR1 signaling
plays an essential role in GnRH biology, potentially linking metabo-
lism with reproduction.
Keywords beta-klotho; congenital hypogonadotropic hypogonadism;
fibroblast growth factor 21; fibroblast growth factor receptor 1
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Introduction
Congenital hypogonadotropic hypogonadism (CHH) is a disorder
characterized by absent or partial puberty and infertility due to
isolated gonadotropin-releasing hormone (GnRH) deficiency. When
CHH is associated with anosmia, the term Kallmann syndrome (KS)
is used. The genetics of CHH is complex with mutations in over 30
genes known to be involved, and with both classical and complex
modes of inheritance, such as oligogenicity (Boehm et al, 2015;
Stamou et al, 2016).
Fibroblast growth factor receptor 1 (FGFR1) is essential for cell
proliferation, differentiation, and migration during embryonic devel-
opment. Gain-of-function mutations in FGFR1 cause several
skeletal disorders such as Pfeiffer syndrome (MIM: 101600) and
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Jackson–Weiss syndrome (MIM: 123150). In 2003, FGFR1 was iden-
tified as the first gene underlying the autosomal dominant form of
KS (Dode et al, 2003), and subsequently, loss-of-function FGFR1
mutations were identified in CHH patients with normal olfaction
(Pitteloud et al, 2006). Altogether, FGFR1 mutations are present in
approximately 10% of CHH cases and are often associated with
incomplete penetrance and variable expressivity (Miraoui et al,
2011). Non-reproductive defects associated with FGFR1 mutations in
CHH patients include anosmia, cleft lip/palate, dental agenesis and
split-hand/foot malformation (Costa-Barbosa et al, 2013; Villanueva
et al, 2015).
The identification of a KS patient carrying an FGFR1 p.L342S
mutation was informative in identifying FGF8 as a critical ligand of
FGFR1 in GnRH biology and in documenting FGF8 as a gene
mutated in CHH. The FGFR1 L342S mutant selectively disrupts
FGF8 signaling leaving FGF1 or FGF2 signaling unaffected (Pitteloud
et al, 2007). This observation led to the identification of FGF8 as a
critical morphogen for GnRH neuron ontogenesis (Pitteloud et al,
2007; Chung et al, 2008; Falardeau et al, 2008). Subsequently,
several other mutations were identified in genes within the FGF8
genetic network (e.g. IL17RD and FGF17), thus reinforcing the
importance of the FGF8/FGFR1 pathway in CHH pathogenesis
(Miraoui et al, 2013).
Murine studies have documented and characterized the role of
FGFR1, not only in GnRH neuron fate specification, but also in
GnRH network homeostasis. Mice with dominant-negative FGF
receptor (dnFGFR) targeted to GnRH neurons exhibit delayed
puberty, early reproductive senescence, and loss of > 50% of GnRH
neurons in adulthood (Tsai et al, 2005). Furthermore, intracere-
broventricular (ICV) injection of anti-FGFR1 antibodies induces
rapid and significant weight loss, indicating a role of Fgfr1 in the
central regulation of metabolism (Sun et al, 2007). Because Fgf8
expression is mostly restricted to embryonic development (Fon
Tacer et al, 2010), we hypothesized that a different ligand for
FGFR1 might be implicated in postnatal GnRH biology. FGF21, an
endocrine FGF mainly secreted by the liver, has been identified as a
major peripheral and central metabolic regulator (Owen et al,
2015). FGF21 binds with low affinity to heparan sulfate and requires
b-Klotho as co-receptor to signal preferentially through its receptor,
FGFR1 isoform c (FGFR1c; Goetz et al, 2007; Kurosu et al, 2007;
Ogawa et al, 2007). Notably, b-Klotho competes with FGF8 for the
same binding site in the immunoglobulin D3 domain of FGFR1c
(Goetz et al, 2012). We thus hypothesized that defects in the
FGF21/KLB/FGFR1 signaling pathway may underlie GnRH defi-
ciency in both humans and rodents.
Results
The CHH-associated FGFR1 L342S mutation alters
FGF21 signaling
The FGFR1 p.L342S mutation identified in a KS proband (Pitteloud
et al, 2007) disrupted not only FGF8 signaling, but also FGF21
signaling (Fig 1A and B), consistent with the same binding pocket
on FGFR1c competed between FGF8 and b-Klotho (Goetz et al,
2012). These data led to the hypothesis that FGF21 signaling
through FGFR1c and b-Klotho might be important for GnRH neuron
biology. Interestingly, the KS patient harboring the p.L342S
mutation also exhibits metabolic phenotypes: he is obese (BMI of
30 kg/m2) with increased fat mass (40% by DEXA, > 97th percen-
tile; Kelly et al, 2009), and severe insulin resistance (evaluated by
hyperinsulinemic euglycemic clamp study, low glucose disposal rate
at 1.5 mg/kg/min; Bergman et al, 1985).
CHH patients harbor putative pathogenic variants in KLB,
encoding the FGF21 co-receptor b-Klotho
Targeted sequencing in an unselected cohort of CHH patients
(n = 334) revealed no rare sequencing variants (RSVs) in FGF21. In
contrast, seven heterozygous putative pathogenic RSVs in KLB were
identified among 13 CHH probands: p.R309W, p.R309Q, p.R424C,
A B
Figure 1. FGFR1 L342S luciferase assays.
A, B Reporter activity of FGFR1 WT and L342S stimulated with increasing doses of FGF8 (A) and FGF21 (B). FGFR1 L342S severely affects FGF8 signaling, with a 28-fold
increase in EC50 (P < 0.001). L342S also impairs FGF21 signaling, with a 20% reduction in maximal response (P = 0.001). The experiments were repeated three
times. Data were plotted as mean  SEM. Maximal responses and EC50 of mutants were compared to WT by F-test. WT, wild type; EV, empty vector.
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p.A574T, p.F777delF, p.K815E, p.L1011P (Fig EV1A, Table 1). None
of these variants were predicted to affect splicing. The inframe dele-
tion (p.F777delF) was identified in seven unrelated patients of Euro-
pean ancestry and was not seen in our in-house reproductively
normal controls (n = 191). Recurrent pathogenic variants are
uncommon in CHH, except for a few founder mutations such as
PROKR2 p.L173R, GNRH1 c.18-19insA, and GNRHR p.R139H (Bouli-
gand et al, 2009; Avbelj Stefanija et al, 2012; Beneduzzi et al, 2014;
Choi et al, 2015). Haplotype analysis based on sequence variants
within KLB was insufficiently informative to distinguish between a
founder effect and a mutational hot spot for p.F777delF. This variant
is significantly more frequent in the CHH cohort compared to ethni-
cally matched controls from ExAC database (P = 0.01), as are the
other KLB mutations except p.R309W and p.K815E (Table 1). In
addition, none of the identified KLB variants were found in a
homozygous status in the ExAC database.
KLB variants have impaired functionality in vitro
The functional effect of the identified KLB variants on FGF21 signal-
ing was tested via cell-based reporter gene assay (Raivio et al,
2009). L6 myoblast cells expressing wild-type (WT) FGFR1c and
KLB showed a typical sigmoid dose–response curve and elicited a
fourfold increase in the activity of the osteocalcin reporter when
treated with increasing doses of rFGF21 (0–20 nM; Fig 2A and B).
All mutants, except R309W, exhibited significantly decreased maxi-
mal response to FGF21 compared to WT (P < 0.05; Fig 2A and B);
R309W exhibited a threefold increase in EC50 compared to WT
(0.52 M vs. 0.15 M, P < 0.001), suggesting a decreased affinity for
FGF21.
Through biochemical studies, we have previously shown that
KLB enhances FGF21-FGFR1c binding and hence promotes FGF21
signaling by simultaneously tethering FGF21 and FGFR1c to itself
through two distinct sites (Goetz et al, 2012). To test whether the
reduced FGF21 signaling was due to a significant defect in the recep-
tor complex formation, we tested the interaction between KLB
mutants and FGFR1c through a co-immunoprecipitation (co-IP)
assay. All of the KLB mutants co-precipitated with FGFR1c to the
same extent as the wild-type KLB (Fig 2C), indicating that the KLB
mutants do not exhibit a major defect in the binding to FGFR1.
Overall expression levels of the KLB mutants were similar to WT
except for R309W which was slightly decreased vs. WT (Fig EV1B).
However, the mature KLB fractions of R309W, R424C, K815E, and
L1011P were decreased (Fig EV1B), suggesting defects in protein
glycosylation. The R309W, R309Q, F777delF, K815E, and L1011P
mutants exhibited significantly less cell surface expression
compared to WT (Fig 2D), consistent with their impaired signaling
(Fig 2A and B). Collectively, our in vitro studies showed decreased
function of the KLB mutants either through reduction in signaling,
ligand affinity, or expression. Furthermore, the KLB F777delF and
FGFR1 R78C mutants co-occurring in Subject 9 (Table 2) were
further tested using the same FGF reporter assay to model the
effect of digenicity in the FGFR1 pathway. While the individual
KLB F777delF or FGFR1 R78C mutants each evoked a decreased
response (15 and 20%, respectively, P < 0.05), the pairing of the
co-receptor/receptor mutants showed further decreased activity
(35%), confirming an additive effect of the digenic mutation
(P < 0.05, Fig 2E).
KLB mutants fail to rescue KLB homolog function in
Caenorhabditis elegans
To investigate the functional effect of KLB mutations in vivo, we
performed rescue assays in C. elegans (Neumann-Haefelin et al,
2010). The role of FGFR and klotho proteins as regulators of meta-
bolic homeostasis is evolutionarily conserved in the nematode
C. elegans (Kokel et al, 1998; Polanska et al, 2011). Caenorhabditis
elegans has a single FGFR homolog, egl-15 (DeVore et al, 1995) and
two Klotho/KLB homologs, klo-1 and klo-2 (Polanska et al, 2011).
Double mutants of klo-1 (ok2925) and klo-2 (ok1862) are viable but
subfertile with a reduction of ~40% in egg laying compared to WT.
In addition, these worms display a fluid homeostasis phenotype,
manifesting as the appearance of hollow cysts within the body
cavity in 31% of animals (n = 174, Fig 2F and G); this phenotype is
Table 1. Summary of KLB mutations identified in patients with congenital hypogonadotropic hypogonadism.
KLB
mutations
Nucleotide
change
Number of subjects
MAF
ExAC
P-
value
SIFT/
PPH2
In vitro studies
Rescue
assay in
Caenorhabditis
elegans
Interpretation
ACMG
guidelines
CHH
(n = 334)
Control
(n = 191)
FGF21
signaling
Cell
surface
expression
Overall
expression
Maturation
level
p.R309W c.925C>T 1 0 8.9e105 0.07 2/2 ↓ ↓ ↓ ↓ None Likely
pathogenic
p.R309Q c.926G>A 1 0 0 0.01 1/2 ↓ ↓ NS NS Partial Likely
pathogenic
p.R424C c.1270C>T 1 0 0 0.01 1/2 ↓ NS NS ↓ Partial Likely
pathogenic
p.A574T c.1720G>A 1 0 0 0.04 1/2 ↓ ↑ NS NS Partial Likely
pathogenic
p.F777delF c.2329delTTC 7 0 0.004 0.01 NA ↓ ↓ NS NS None Pathogenic
p.K815E c.2443A>G 1 1 0.001 0.57 2/2 ↓ ↓ NS ↓ Partial Likely
pathogenic
p.L1011P c.3032T>C 1 0 6.0e105 0.049 2/2 ↓ ↓ NS ↓ None Uncertain
significance
CHH, congenital hypogonadotropic hypogonadism; MAF, minor allele frequency; P-value, Fisher’s exact test of allele frequency in CHH cohort versus ethnically
matched controls from ExAC database; PPH2, polyphen-2; ↓, decreased; ↑, increased; NS, not significant. ACMG, American College of Medical Genetics and
Genomics (Richards et al, 2015).
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presumably related to the role of klo-1 in excretory canal develop-
ment in C. elegans (Polanska et al, 2011). Transgenic expression of
wild-type human KLB under the control of 5ʹ upstream sequences
(referred to as “promoter”) of either the C. elegans klo-1 or klo-2
was able to rescue the worm klo-2; klo-1 double mutant phenotype
(Fig 2F and G). In contrast, transgenic expression of human KLB
containing F777delF, R309W, or L1011P mutations under the
control of the klo-1 promoter failed to rescue the cyst phenotype
◀ Figure 2. KLB functional assays.A, B Reporter activity of KLB WT and mutants stimulated with FGF21. The maximal response to FGF21 is impaired (P < 0.05) in all but one KLB mutant, R309W, which
exhibits nevertheless increased EC50 compared to WT (P < 0.001). All luciferase activity assays were plotted as mean  SEM of three independent experiments.
Maximal responses and EC50 of mutants were compared to wild type (WT) by F-test.
C Immunoprecipitation (IP) assay. HEK293T cells were transfected with flag-tagged KLB and myc-tagged FGFR1c. KLB was immunoprecipitated with monoclonal
anti-flag antibody. KLB was detected with anti-flag antibody and FGFR1c with anti-myc antibody. IB: immunoblotting. Experiments were repeated twice with
similar results. Lanes presented in the figure are from different blots and were juxtaposed.
D Cell surface expression of KLB WT and mutants. Data are presented as the mean  SEM of three independent experiments; mutants were compared to WT by
unpaired t-test.
E Activity of the double mutant FGFR1 R78C and KLB F777delF. The double mutant exhibits a further decrease in response to FGF21 compared to either single mutant
(P < 0.05). The experiments were repeated three times, and data were plotted as mean  SEM. Maximal responses of mutants were compared to WT by F-test.
F Representative DIC images of rescue assays in Caenorhabditis elegans. Worms deficient in both klo-1 and klo-2 develop hollow cysts within their body cavity (panel
2, arrows). Transgenic expression of WT human KLB in klo-1; klo-2 mutant worms rescue this phenotype (panel 3). Transgenic expression of the KLB F777delF
mutant fails to rescue the phenotype (panel 4, arrows).
G Quantification of the rescue assay results. klo-1; klo-2 double mutant worms were injected with human KLB WT and mutant constructs under the control of pklo1
or pklo2 promoters. Each bar represents the average of two to four independent transgenic lines. For each KLB mutant, the percentage of worms with cystic
phenotypes was compared to the klo-1; klo-2 double mutant and to the pklo1:WT controls by Fisher’s exact test.
Data information: WT, wild type; EV, empty vector. *P < 0.05, **P < 0.01, ***P < 0.001, NS: not significant.
Source data are available online for this figure.
Table 2. Clinical phenotypes of congenital hypogonadotropic hypogonadism patients with heterozygous KLB mutations.
Subject
KLB
mutation Sex
Age
at
Dx Inheritance Puberty Olfaction
Additional
reproductive
phenotypes
BMI
(kg/m2)
Metabolic
phenotypes
Other CHH
gene
mutations
1a p.R309W M 25 F A A Cryptorchidism 40 Obesity,
insulin
resistance
None
2 p.R309Q M 28 F P A None 25 Impaired
fasting
glucose
FGF8 p.P26L
3 p.R424C M 31 F A A Cryptorchidism 28 Overweight None
4 p.A574T M 19 F A N Micropenis 22 Impaired
fasting
glucose,
dyslipidemia
PROKR2
p.S188L
5 p.F777delF F 18 F A N None 23 NA GNRHR
p.Q106R
6 p.F777delF F 16 F A H None 17 Underweight None
7 p.F777delF M 18 F A A Cryptorchidism,
micropenis
43 Obesity,
insulin
resistance,
dyslipidemia
None
8 p.F777delF M 19 S P A Reversal 21 Dyslipidemia None
9 p.F777delF M 16 S A A Micropenis,
retractile testes
25 Overweight,
dyslipidemia
FGFR1
p.R78C
10 p.F777delF M 25 S A A Cryptorchidism 26 Overweight None
11a p.F777delF M 16 S A A Hypospadias,
cryptorchidism
20 Insulin
resistance
PROKR2
p.L173R
12 p.K815E M 53 S P A Fertile eunuch 22 None None
13 p.L1011P M 19 F P A Micropenis 20 NA None
Sex: F, female; M, male; Dx, diagnosis; Inheritance: F, familial; S, sporadic; Puberty: A, absent; P, partial; Olfaction: A, anosmia; N, normosmia; H, hyposmia; NA, not
available.
aSubjects from the exome cohort..
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(Fig 2G). All other mutants displayed decreased rescue ability
(Fig 2G).
In summary, all KLB variants have impaired functionality in vitro
and in vivo, and can thus be considered mutations (Table 1). Inte-
grating evidence from population data, computational algorithms,
functional assays, and segregation data according to the guidelines
of the American College of Medical Genetics and Genomics (ACMG;
Richards et al, 2015; Li & Wang, 2017), all KLB variants except
p.L1011P were classified as “pathogenic” or “probably pathogenic”,
while p.L1011P as “variant of uncertain significance” (Table 1).
Genotype–Phenotype correlations
The clinical data of the 11 male and two female CHH patients with
KLB mutations are summarized in Table 2 and Fig 3. Five cases
were sporadic while the remainder (8/13, 62%) exhibited a familial
inheritance, which is twice the known overall frequency of familial
cases in CHH (30%; Raivio et al, 2009).
The majority of patients (7 males, 2 females) presented with
absent puberty and micropenis and/or cryptorchidism in males—
phenotypes consistent with severe GnRH deficiency; four patients
exhibited partial puberty, indicating less severe GnRH deficiency.
One patient underwent spontaneous reversal after discontinuing
testosterone treatment (Patient 8; Raivio et al, 2007). The majority
of patients (11/13) had abnormal olfaction and were thus diagnosed
as KS. In addition, nine of 13 of these young CHH patients had meta-
bolic phenotypes, including overweight/obesity, dyslipidemia, and/
or insulin resistance; one patient was underweight at diagnosis
(Table 2). Among the seven patients carrying the p.F777delF muta-
tion, only one had partial puberty and reversal of HH. This patient
carries only the KLB mutation (Table 2). Additional CHH-associated
phenotypes were highly variable with polydactyly, renal pheno-
types, synkinesia, or cleft lip and palate present in one patient each
(Appendix Case Reports).
DNA from family members was available for 10 pedigrees, none
of which revealed de novo mutations. Variable expressivity and
Figure 3. Pedigrees of CHH probands harboring KLB mutations.
All identified KLBmutations are heterozygous. CHH, congenital hypogonadotropic hypogonadism; circles denote females; squares denote males; arrows depict probands; WT
denotes wild type.
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incomplete penetrance, common features in CHH, were observed in
families harboring KLB mutations: family members in pedigrees 2,
4, and 6 carry the same KLB mutation as the proband yet exhibit
attenuated phenotypes (delayed puberty or isolated anosmia), indi-
cating variable expressivity. Asymptomatic carriers are present in
families 2, 5, 7, 8, 9, and 13. Five probands (35%) were found to
carry another heterozygous mutation in a known CHH gene in addi-
tion to the KLB mutation (Fig 3, Table 2), comprising FGF8 (Subject
2), PROKR2 (Subjects 4 and 11), GNRHR (Subject 5), and FGFR1
(Subject 9). Additional mutations were not observed in our in-house
control subjects (n = 191). The additional mutations are predicted
to be deleterious in silico and four of five have been previously
shown to be loss of function in vitro (Appendix Case Reports).
Within the families with mutations in two different genes (Pedigree
4 and 5), we observed a more severe phenotype in the probands
with digenic mutations compared to their parents with single gene
defects. Further, among the four probands with partial GnRH defi-
ciency, three patients carry heterozygous KLB mutation alone. These
observations suggest that some degree of oligogenicity is present in
this population and that the genetic load may impact the phenotypic
severity. Metabolic data were not available for family members, and
therefore, we are unable to assess these features in family members
carrying KLB mutations.
Considering the broader FGF21/KLB/FGFR1 gene network in
this CHH cohort, 38 FGFR1 mutations were identified (including
a homozygous one) in 45 of 334 (13%) of patients
(Appendix Table S1); these include the patient (Subject 9) carrying
heterozygous mutations in KLB and FGFR1 mentioned above
(Table 2). Thus, in total, 57 of 334 (17%) of CHH patients harbor
mutation(s) in FGF21/KLB/FGFR1, either as monoallelic mutations
or as digenic combinations.
Klb-deficient mice exhibit delayed puberty and subfertility due to
a hypothalamic defect
To further establish the role of Klb in GnRH biology, we studied the
reproductive phenotype of Klb knockout mice (KlbKO). In the
C57BL/6J pure background, we observed a high neonatal mortality
of KlbKO mice (KlbKO represented 5–10% of the litters versus the
25% expected from heterozygous breeding pairs). The KlbKO mice
exhibited marked delay of vaginal opening and first estrus (Fig 4A
and B), measures of the initiation and completion of puberty,
respectively. Notably, KlbKO mice displayed reduced growth, with a
lower weight that persists in adulthood (Fig 4C and D). However,
the reduced weight alone did not explain the delayed puberty, as
KlbKO females reached puberty at a significantly lower weight than
WT (Fig EV2A and B). Uterine weight, body composition, food
intake, energy expenditure, and glucose tolerance were similar to
WT (Figs 4E and EV2C–J). Serum insulin, leptin, and cholesterol
levels were normal (Fig EV2K–L).
In accordance with their reduced ovarian weight (normalized to
total body weight) and their decreased number of corpora lutea
(Fig 4F–I), KlbKO adult females of 3–4 months old had irregular
estrous cycles compared to their WT counterparts, with a significant
decrease of the time spent in estrous (Fig 4J–K). In addition, KlbKO
mice displayed reduced fertility compared to WT mice, yielding
significantly fewer litters in the continuous mating protocol fertility
test breeding with WT males (Fig 4L).
The exposure of WT female mice to sexually mature male pher-
omones leads to the initiation of proestrus, including increased
hypothalamic secretion of GnRH and a preovulatory LH surge
(Bronson & Stetson, 1973). In contrast, KlbKO females exhibit a
substantially blunted LH surge compared to WT (Fig 4M).
Intraperitoneal (IP) GnRH injections elicited a robust rise in LH in
both WT and KlbKO mice, excluding a pituitary defect (Fig 4N).
Furthermore, IP Kisspeptin (Kp-10) injections also induced LH
secretion in both in WT and KlbKO females, suggesting that GnRH
neurons are present and can respond to stimulation (Fig 4O).
These results illustrate an implication of Klb in hypothalamic GnRH
secretion, consistent with a contribution of Klb to the central regu-
lation of reproduction.
As KLB mutations are heterozygous in CHH patients, we further
tested whether Klb heterozygous (KlbHET) female mice display a
reproductive phenotype. We observed that KlbHET exhibited similar
reproductive defects as KlbKO mice: disrupted estrous cycle
(Fig EV3A and B) and blunted LH surge at the estrus stage
(Fig EV3C–F). In addition, the short-term fertility test showed a
reduced pregnancy rate in KlbHET females, indicating a fertility
◀ Figure 4. Lack of Klb in female mice leads to defects in sexual maturation with delay of puberty, altered cyclicity, reduced LH secretion, and reduced fertility.A–C Altered pubertal development in KlbKO mice compared to WT littermates including delayed vaginal opening (KO: n = 12; WT: n = 11) and first estrous (KO: n = 7;
WT: n = 11), expressed as cumulative percentage as a function of age (Gehan–Breslow–Wilcoxon test), and reduced body weight (KO: n = 7; WT: n = 7; two-way
RM ANOVA).
D Body weight of adult KlbKO mice (n = 10) compared to WT littermates (n = 15), using unpaired t-test.
E Body composition expressed as percentage of fat mass in KlbKO (n = 20) and WT mice (n = 23), unpaired t-test.
F Representative low magnification picture of the uterus and ovaries in WT and KlbKO mice. Scale bar 1 mm.
G Hematoxylin–eosin-stained ovarian representative sections of KlbKO and WT mice at 3 months (CL: corpora lutea). Scale bar: 600 lm.
H Normalized ovarian weight expressed as ovary/body weight ratio in KlbKO (n = 7) and WT mice (n = 10), unpaired t-test.
I Quantification of corpora lutea per ovary in KlbKO (n = 5) and WT (n = 5) adult females, unpaired t-test.
J Representative estrous cycle patterns of 3- to 4-month-old WT and mutant females, demonstrating marked alteration in KlbKO.
K Quantification of time spent in different estrous cycle phases in KlbKO (n = 13) and WT (n = 17) adult females, unpaired t-test.
L Fertility evaluated as number of litters per female and litter size in KlbKO (n = 6) and WT littermates (n = 5) in a continuous mating protocol (7 months), unpaired
t-test.
M KlbKO females display blunted preovulatory LH surge in male-induced proestrous (MIP) test (WT Di: n = 5; WT Pro: n = 8; KO Di: n = 5; KO Pro: n = 5).
N GnRH test: basal blood LH levels and 30 min after intraperitoneal GnRH injection (0.25 lg) show LH release in both KlbKO (n = 5) and WT littermates (n = 7).
O Kisspeptin test: blood LH levels at basal state and 30 min after intraperitoneal Kisspeptin injection (Kp-10; 1 nmole) in WT (n = 5) and KlbKO (n = 5) female mice.
Data information: Multiple comparison analysis of LH levels was performed using a two-way ANOVA followed by Fisher’s LSD test (for MIP) and Sidak’s multiple
comparison test (for GnRH and Kisspeptin tests). Values shown are mean  SEM; *P < 0.05, **P < 0.01, ***P < 0.001. ns: not significant.
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defect (Fig EV3G). These findings indicate that haploinsufficiency
for Klb leads to significant reproductive defects in mice.
Klb is implicated in GnRH biology in the postnatal period but not
during embryonic development
To further explore the defect of GnRH secretion in KlbKO mice,
we first localized and quantified the GnRH neuron population in
adult brains (P90–180). A normal complement of hypothalamic
GnRH neurons and axonal projections to the median eminence
(ME) was found in KlbKO mice (Fig 5A–C), indicating normal
embryonic GnRH neurons development. We next investigated
the hypothalamic expression of Gnrh and other genes known to
be important for puberty and GnRH biology (i.e., Kiss1, Npy,
Pomc, and Lepr); expression of these genes was not altered in
KlbKO mice (Fig EV4A and B). Finally, we found no alteration
A
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in GnRH vesicular pool at the nerve terminals in KlbKO mice
(Fig EV4C), indicating that GnRH peptide synthesis and trans-
port are not affected. These results indicate that Klb deficiency
cause a defect in GnRH neuron homeostasis rather than
development.
We further characterized the spatiotemporal expression pattern
of Fgfr1 and Klb in embryonic and postnatal tissues critical for
GnRH neuron biology, as well as in immortalized GnRH cell lines
(Gn11 and GT1-7 cells; Fig 5D and E). As expected, Fgfr1 expres-
sion was high in the immature Gn11 cells as well as in embryonic
tissues. Postnatally, Fgfr1 expression increased in the POA at
weaning and persisted into adulthood (Fig 5D). Notably, Klb
expression did not parallel Fgfr1 expression, in that it was very
low to absent in the embryonic brain and nose (Fig 5E). In
contrast, higher levels of Klb were identified in the POA at birth
and persisted until weaning with a further increase in adulthood
(Fig 5E). These results further support a role of FGF21/KLB/
FGFR1 signaling in the postnatal modulation of GnRH biology
rather than embryonic development, which has previously been
associated with FGF8/FGFR1 signaling.
A
D E
B
C
Figure 5. Intact positioning of GnRH neurons in KlbKO mice.
A Representative brain sections from wild-type and KlbKO adult females showing GnRH neuron cell bodies and fibers at the level of the ovlt in the POA (upper panel)
and at the level of the median eminence in the mediobasal hypothalamus (ME, lower panel) level. Scale bars, 200 lm.
B Analysis of GnRH neuron distribution along the rostro-caudal axis from the level of the medial septum/diagonal band of broca (MS/DBB, 1,080 lm) through the
organum vasculosum of the lamina terminalis (ovlt, 0 lm), to the level of the median eminence (ME, +2,160 lm). WT: n = 7; KO: n = 4.
C Quantification of total hypothalamic GnRH neurons in adult KlbKO females and WT littermates (WT: n = 8; KO: n = 4). Differences in GnRH cell number between
groups were assessed using unpaired t-test.
D, E Gene expression profiles in immature (Gn11) and mature (GT1-7) immortalized GnRH neurons and dissected tissues at embryonic day E13.5 (nose and brain) and
different postnatal ages from postnatal day 0 (P0) to adulthood (n ≥ 3 per group). Differences between groups were assessed using one-way ANOVA followed by
Fisher’s LSD test.
Data information: Values shown are mean  SEM; different letters (abcde) indicate significant differences between groups (P < 0.05).
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FGF21 stimulates neurite outgrowth in mature GnRH neurons
in vitro and induces GnRH secretion in ME explants ex vivo
The cyclic release of GnRH peptide during the ovarian cycle in the
pituitary portal system requires periodic neuroglial remodeling by
molecules such as semaphorins and nitric oxide in the adult ME (De
Seranno et al, 2004; Prevot et al, 2010; Giacobini et al, 2014;
Parkash et al, 2015). FGF21 has recently been shown to be able
to promote neurite outgrowth in vitro (Huang et al, 2013).
Consistently, we found that recombinant FGF21 (rFGF21) increased
neurite length in mature immortalized GnRH neurons (GT1-7)
in vitro (Fig 6A–C). To investigate the possibility that FGF21 may
also act directly on GnRH neurons to modulate their function
in vivo, we isolated GnRH neurons from adult Gnrh::gfp mice using
fluorescence-activated cell sorting (FACS) and analyzed Klb expres-
sion. A twofold enrichment of Klb transcripts was found in GnRH
neurons (Fig 6D). To further explore the role of FGF21 on GnRH
neuronal function, we studied the effects of rFGF21 treatment on
A
D
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Figure 6.
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GnRH secretion in living ME explants obtained from WT and KlbKO
mice. Exogenous rFGF21 promoted robust GnRH release in a dose-
dependent manner in WT mice, but not in KlbKO mice (Fig 6E).
These results thus raise the possibility that peripheral FGF21 modu-
lates GnRH secretion by acting directly on GnRH neuroendocrine
terminals in the ME.
Peripheral FGF21 reaches GnRH neurons through fenestrated
vessels of ME or OVLT in vivo
We next examined whether peripheral FGF21 could reach hypotha-
lamic GnRH neurons in vivo. Fluorescently labeled rFGF21 was
injected intravenously to Gnrh::gfp mice 1 min before sacrifice. At
this short interval, fluorescent rFGF21 was seen in the parenchyma
of the ME and the organum vasculosum of the lamina terminalis
(OVLT; Figs 6F and G, and EV5), where GnRH nerve terminals and
GnRH dendrites are, respectively, distributed and extend beyond the
blood–brain barrier (BBB; Ciofi et al, 2009; Herde et al, 2011).
While circulating fluorescent rFGF21 remained trapped in the capil-
laries of the BBB (empty arrowheads, Fig 6F and G), it extravasated
from the fenestrated vessels of the OVLT and the ME (Figs 6F and
G, and EV5). GnRH neuroendocrine terminals in the external zone
of the ME were seen to be surrounded by bloodborne fluorescent
rFGF21 flooding the ME (arrows, Figs 6G and EV5). GnRH dendrites
in the OVLT were found to be able to capture this circulating fluo-
rescent rFGF21 and transport it toward the respective GnRH cell
bodies (arrows, Figs 6F and EV5). Altogether, morphological data
suggest that hypothalamic GnRH neurons can readily have access to
peripheral FGF21.
Discussion
Reproductive fitness is known to be tightly linked to energy avail-
ability, although the exact molecular mechanisms are still unknown
(Bronson, 1986; Cahill, 2006). The hepatokine FGF21, a key central
metabolic regulator (Liang et al, 2014; Owen et al, 2015), may
constitute such a link between metabolism and reproduction. Our
finding of KLB mutations impairing FGF21 signaling in patients with
congenital GnRH deficiency with a high frequency of associated
metabolic defects supports this concept. Studies of Klb-deficient
mice, which exhibit delayed puberty and subfertility partly due to a
hypothalamic defect, are consistent with a role of Fgf21 in regulat-
ing reproduction. A previous report showed that Fgf21 transgenic
mice exhibit GnRH deficiency with infertility by repressing the vaso-
pressin–kisspeptin pathway (Owen et al, 2013). Thus, both defi-
ciency and excesses of FGF21 may lead to defects in GnRH function,
consistent with the concept that a tightly regulated energy balance
is required for optimal reproductive capacity.
While no CHH patients were found to harbor mutation in FGF21,
4% exhibit heterozygous mutations in KLB. All KLB mutants were
confirmed to be loss of function in vitro as well as in vivo using a
rescue assay in C. elegans. Notably, the p.F777delF mutation is found
in seven probands of European descent. Although this variant is
present in one out of 133 non-Finnish European controls (0.7%) in
the ExAC database, it is significantly enriched in our CHH cohort
versus controls. As most mutations in CHH are private, this occur-
rence suggests either a mutational hot spot or a founder effect (Avbelj
Stefanija et al, 2012; Choi et al, 2015). The clinical spectrum ranges
from severe GnRH deficiency with micropenis and cryptorchidism to
milder forms such as CHH with reversal or fertile eunuch syndrome.
This phenotypic variability is also observed among the seven CHH
probands harboring the p.F777delF mutation, suggesting that other
genetic or environmental factors may contribute to the phenotype.
Additional mutations in other CHH genes were indeed found in five
out of 13 patients (38%) including three patients with the p.F777delF
mutation; this is compatible with an oligogenic model of inheritance
that has been firmly established for other CHH genes (Sykiotis et al,
2010; Quaynor et al, 2011; Miraoui et al, 2013). To date, there
remain 50% of CHH patients for whom no pathogenic mutation is
known (Boehm et al, 2015), suggesting that additional mutations in
currently unknown genes remain to be discovered.
Metabolic defects have been previously described in CHH
patients and are thought to be secondary to sex steroid deficiency
leading to unfavorable changes in body composition and inflamma-
tion (Zitzmann, 2009). Indeed, these metabolic parameters usually
◀ Figure 6. rFGF21 induces neurite outgrowth in GnRH neurons in vitro, stimulates GnRH secretion ex vivo, and reaches GnRH neurons by fenestrated vesselsin vivo.
A Representative images of GT1-7 immortalized GnRH neurite traces after 48 h of culture in control medium (SFM) alone or with 100 nM rFGF21 (n = 4 per group).
Scale bar 30 lm.
B Average of the longest neurite length of GT1-7 cells in aforementioned conditions, unpaired t-test (n = 4 per group).
C Neurite length distribution histogram showing significant increase of cells with longer neurites (> 80, 60–80 lm) and reduced number with shorter neurites
(20–40 lm) after rFGF21 treatment, unpaired t-test (n = 4 per group).
D Isolation protocol of GnRH neurons from GnRH::GFP mice by fluorescence-activated cell sorting (FACS) and Klb mRNA expression quantification in GnRH-positive
(POS) and GnRH-negative (NEG) hypothalamic FACS-isolated cells (n = 3 per group), unpaired t-test. POA, preoptic area of the hypothalamus.
E GnRH peptide content in conditioned medium from ME explant cultures treated with increasing doses of rFGF21 (n = 5 per group) for 20 min. Data were analyzed by
two-way ANOVA followed by Sidak’s multiple comparisons test.
F Representative photomicrographs of the preoptic region showing GnRH neurons (GFP, green) and blood vessels from the BBB (empty arrowhead) and the OVLT
(arrowhead) labeled by fluorescent rFGF21 (5 nmol/animal, white staining). Note the presence of white staining in GFP-expressing neuronal processes, dendrites, and
cell body (arrows, inset 10 and 20). Nuclear contrast staining: DAPI; 3V, third ventricle; OVLT, organum vasculosum of the lamina terminalis; oc, optic chiasma. Scale
bar: 150 lm for inset 10 , 40 lm for inset 20 , and 300 lm for other panels.
G Representative photomicrographs showing blood vessels from BBB (empty arrowhead) and in ME (arrowhead) labeled by fluorescent rFGF21 (5 nmol/animal, white
staining) in the tuberal region of the hypothalamus. Note that fluorescent rFGF21 administered intravenously diffuses into ME tissue (white staining, asterisk) where
GnRH neuroendocrine axons are distributed (green, arrows). Nuclear contrast staining: DAPI; ME, median eminence; ARH, arcuate nucleus of the hypothalamus. Scale
bar: 50 lm for inset 10 and 130 lm for other panels.
Data information: Values shown are mean  SEM; *P < 0.05, **P < 0.01, ***P < 0.001.
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improve after initiation of sex hormone replacement therapy
(Tripathy et al, 1998; Naharci et al, 2007; Bayram et al, 2016).
Further, short-term discontinuation of androgen therapy in male
CHH patients leads to mild insulin resistance and increased glucose
levels (Yialamas et al, 2007). Thus, unlike neurosensory hearing
loss or anosmia, metabolic defects are not typically considered as
primary events in CHH, apart from syndromic CHH caused by LEP,
LEPR, or PCSK1 mutations resulting in both GnRH deficiency and
morbid obesity (Jackson et al, 1997; Farooqi et al, 2002, 2007).
Leptin deficiency or resistance leads to a lack of metabolic cues that
signal to the hypothalamus to regulate both energy homeostasis and
fertility (Chehab, 2014). Here, we show that a majority of patients
with KLB mutations (9/13) exhibit hypogonadotropic hypogonadism
with some degree of metabolic defect (i.e. overweight, insulin resis-
tance, and/or dyslipidemia), consistent with the metabolic role of
FGF21/KLB/FGFR1 pathway. However, systematic metabolic
phenotyping at diagnosis and after sex steroid replacement is
required to firmly establish this association.
While Fgfr1 is widely expressed in the brain, Klb expression is
more restricted spatially and temporally, thus delimiting Fgf21 signal-
ing (Bookout et al, 2013). We found that Klb mRNA was barely
detectable during embryonic development in the head and nose, but
it increased significantly after birth and maintained in adult/mature
GnRH neurons, supporting a postnatal role of FGF21/KLB/FGFR1
signaling in GnRH biology. Consistent with the temporal pattern of
Klb expression, we found that KlbKO mice had normal embryonic
GnRH neuron development but exhibited delay puberty, disrupted
cyclicity, and subfertility with an impaired GnRH function. The repro-
ductive defects in the KlbKO mice are less severe than the phenotypes
observed in our CHH patients with heterozygous KLBmutations. This
phenotypic discrepancy between human and mice has been previ-
ously reported for other CHH genes like TACR3 and NSMF (Yang
et al, 2012; Quaynor et al, 2015). Notably, a similar reproductive
phenotype was observed in KlbHET mice, indicating that Klb haploin-
sufficiency causes reproductive defects. This finding provides further
evidence for a pathogenic role of the heterozygous KLB mutations in
human, likely through the mechanism of haploinsufficiency.
In the adult hypothalamus, cyclic GnRH secretion is modulated by
an interactive plasticity involving GnRH neuron terminals, tanycytes,
and endothelial cells through locally secreted molecules such as
semaphorins and nitric oxide (De Seranno et al, 2004; Giacobini et al,
2014; Parkash et al, 2015). While the role of FGF21 in the GnRH
system was previously reported to suppress GnRH upstream signals
such as vasopressin and kisspeptin (Owen et al, 2013), recent studies
have shown that FGF21 may play a role in neuronal protection and
neuronal plasticity (Huang et al, 2013; Leng et al, 2015). Our findings
that FGF21 promotes neurite outgrowth in mature immortalized
GnRH neurons (GT1-7) and stimulates GnRH secretion in living ME
explants suggest a novel role for FGF21 in controlling fertility by
modulating GnRH neuron structural plasticity. Further studies are
warranted to define the exact mechanism of FGF21 action on
neuroglial–endothelial plasticity in vivo and its physiological rele-
vance for the GnRH system. Induced pluripotent stem cell (iPSC)-
derived GnRH neurons (Lund et al, 2016; Poliandri et al, 2017) from
CHH patients with KLB mutations would be an excellent model to
elucidate how the human KLB mutants affect GnRH secretion.
Similar to leptin-sensitive neurons in the arcuate nucleus (Djogo
et al, 2016; Pan & Myers, 2016), GnRH neurons extend their
dendrites and terminals outside the blood–brain barrier (Ciofi et al,
2009; Herde et al, 2011). Therefore, it is tempting to speculate that
GnRH neurons can also directly sense circulating metabolic signals.
Leptin and insulin apparently do not act in this way, because GnRH
neurons do not express leptin receptors (Quennell et al, 2009) and
GnRH neuron-specific deletion of the insulin receptor does not lead
to any reproductive defects (Evans et al, 2014). Our diffusion stud-
ies show that peripheral Fgf21 does not freely cross the BBB, but
rather extravasates quickly from the fenestrated capillaries in the
ME and the OVLT to gain direct access to GnRH neuronal dendrites
and terminals lying outside the BBB (Ciofi et al, 2009; Herde et al,
2011). Taken together with our findings that Klb and Fgfr1 are
expressed in GnRH neurons, and that FGF21 stimulates GnRH
secretion in ME ex vivo, it is likely that GnRH neuron terminals
outside the BBB may perceive peripheral FGF21 promptly and effi-
ciently to adapt GnRH secretion according to the metabolic state of
the individual. It will thus be interesting to evaluate the FGF21 gene
network for mutations in patients with functional hypogonadotropic
hypogonadism (i.e., hypothalamic amenorrhea (Gordon, 2010) and
obesity-related hypogonadotropic hypogonadism; Giagulli et al,
1994), as environmental cues related to energy balance are critical
for reproductive fitness.
Materials and Methods
Subjects
The cohort includes 334 unselected probands with CHH (227 KS
and 107 normosmic CHH, with 3:1 male–female ratio) along with
affected and unaffected family members when available. The diag-
nosis of CHH includes: (i) absent or incomplete puberty by age 16;
(ii) low/normal gonadotropin levels in the setting of low serum
testosterone/estradiol levels; and (iii) otherwise normal anterior
pituitary function and normal imaging of the hypothalamic–pituitary
area (Pitteloud et al, 2002). Olfaction was assessed by self-report
and/or formal testing (Lewkowitz-Shpuntoff et al, 2012). Metabolic
assessments include BMI, fasting glucose and insulin levels, home-
ostasis model of assessment of insulin resistance (HOMA-IR; Tam
et al, 2012), and lipid profile at presentation. Additionally, one
patient underwent a hyperinsulinemic euglycemic clamp as previ-
ously described (Pitteloud et al, 2005). The controls include 191 in-
house reproductively healthy subjects of non-Finnish European
origin (Raivio et al, 2009).
Genetic studies
Genomic DNA was extracted from peripheral blood samples using
previously described methods (Miraoui et al, 2013). The coding
exons and intronic splice regions (≤ 6 bp from the exons) of FGF21
(NM_019113.2) and KLB (NM_175737) were analyzed by exome
(n = 83) or Sanger sequencing (n = 251). Exome capture was
performed using the SureSelect All Exon capture (Agilent Technolo-
gies, Santa Clara, CA USA) and sequenced on the HiSeq2500
(Illumina, San Diego CA USA). Raw sequences (fastq files) were
analyzed using an in-house pipeline that utilizes published algo-
rithms: the Burrows-Wheeler Alignment tool (BWA; Li & Durbin,
2009) for mapping the reads to the human reference sequence
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(GRCh37), and the Genome Analysis Toolkit (GATK; DePristo et al,
2011) for the detection of single nucleotide variants (SNVs) and
insertion/deletions (Indels). The resulting variants for both exome
and Sanger sequences were annotated using SnpEff version 4.0
(Cingolani et al, 2012) and dbNSFP version 2.9 (Liu et al, 2013) to
calculate minor allele frequency (MAF) and protein functional
predictions.
A putative pathogenic variant is defined as (i) non-synonymous
rare variant with MAF < 1% in both our in-house controls
(n = 191; Raivio et al, 2009) and ethnically matched controls from
the Exome Aggregation Consortium (ExAC, http://exac.broadinsti
tute.org); (ii) nonsense, frameshift, inframe insertion/deletion, splic-
ing variants (predicted to affect splicing by at least two out three
programs including Human Splice Finder (Desmet et al, 2009),
MaxEnt (Desmet et al, 2009), and NNSplice (Reese et al, 1997), or
missense variants predicted to be damaging by either SIFT (Ng &
Henikoff, 2001) and Polyphen-2 (Adzhubei et al, 2010). A putative
pathogenic variant is confirmed as a mutation when shown to be
loss of function in functional assays (see below). ACMG guidelines
for interpretation of sequencing variants (Richards et al, 2015; Li &
Wang, 2017) were also applied to assess the pathogenicity of identi-
fied variants.
All subjects were also screened for known CHH genes via Sanger
(n = 251) or by exome sequencing (n = 83): [KAL1 (NM_000216.2),
FGFR1 (NM_023110.2), FGF8 (NM_033163.3), PROKR2 (NM_
144773.2), PROK2 (NM_001126128.13), GNRHR (NM_000406.2),
GNRH1 (NM_000825.3), KISS1R (NM_032551.4), KISS1 (NM_
002256.3), TACR3 (NM_001059.2), TAC3 (NM_013251.3), NSMF
(NM_001130969.1), HS6ST1 (NM_004807.2), DUSP6 (NM_001946.2),
FGF17 (NM_003867.2), FLRT3 (NM_198391.2), IL17RD (NM_
017563.3), and SPRY4 (NM_030964.3)]. Variants were confirmed by
Sanger sequencing of both strands and with duplicate PCRs, and are
described according to HGVS nomenclature (den Dunnen &
Antonarakis, 2000).
The clinical and genetic studies were approved by the Institutional
Review Board of Partners Healthcare and the ethics committee of the
University of Lausanne, and were conducted in accordance with the
guidelines of the Declaration of Helsinki. All participants provided
written informed consent prior to study participation. Our datasets
were obtained from subjects who have consented to the use of their
individual clinical and genetic data for biomedical research, but not
for unlimited public data release. Therefore, we submitted the data to
the European Genome-phenome Archive (EGAS00001002568), and
researchers can apply for access to the raw data.
Functional studies
Generation of KLB expression constructs
Human KLB cDNA in pCR4-TOPO vector (Plasmid ID
HsCD00341606, Harvard Medical School) was used to generate
constructs with N-terminus flag-tagged and C-terminus HA-tagged
KLB cDNA in pcDNA3.1 + vector, which were further used as
template for mutagenesis using QuikChange II XL Site-Directed
Mutagenesis kit (Agilent Technology).
FGF8/FGF21 signaling studies
Signaling activity of FGFR1 and KLB mutants was assessed using
the osteocalcin FGF response element luciferase in a L6 myoblast
cell model. L6 cells (sourced from ATCC) were transiently trans-
fected with N-terminus myc-tagged FGFR1 cDNA as previously
described (Raivio et al, 2009), and HA-tagged KLB cDNA expression
vector was added to the DNA mix when appropriate. 24 h post-
transfection, cells were treated with recombinant FGF8 or FGF21
(16 h, 0–20 nM, except for double mutant assay 0–10 nM) as indi-
cated and subsequently analyzed for luciferase activity. In each
experiment, FGFR1 and KLB mutant values were expressed as a
percentage of the maximal WT response and plotted with three-
parameter agonist dose–response curves using Prism software (ver-
sion 7; GraphPad). Transfection assays were performed in triplicate
and repeated three times. The activity of each KLB/FGFR1 mutant
was compared to WT in terms of EC50 dose and the maximal FGF
response.
Co-immunoprecipitation assay
HEK293T cells (sourced from ATCC) were transiently transfected
with N-terminus flag-tagged KLB and/or myc-tagged FGFR1 using
FuGENE 6 Transfection Reagent (Promega, Madison, WI, USA)
according to the manufacturer’s protocol. 48 h after transfection
cells were lysed in lysis buffer (50 mM Tris–HCl pH8, 150 mM
NaCl, 2 mM EDTA, 1% Triton X-100) supplemented with a cocktail
of protease inhibitors (Thermo Fisher Scientific, Waltham, MA,
USA). Clarified lysates were immunoprecipitated using monoclonal
anti-flag (Sigma-Aldrich, Saint Louis, MO, USA) according to the
manufacturer’s instructions. Precipitated proteins were processed as
previously described (Bouilly et al, 2014). KLB was revealed using
mice monoclonal anti-flag (Sigma-Aldrich, Saint Louis, MO, USA),
and FGFR1 was detected using mice monoclonal anti-myc (Millipore
Corporation, Billerica, MA, USA). Experiments were repeated twice
with consistent results.
Ectopic protein expression and glycosylation analysis
The expression and maturation studies were performed in COS7
cells (sourced from ATCC) transiently transfected with C-terminus
HA-tagged WT or mutated KLB constructs. As b-Klotho is an
N-linked glycosylated protein, cell lysates were further subjected
to enzymatic deglycosylation with peptide N-glycosidase F
(PNGase F) and endoglycosidase H (EndoH), as described (Raivio
et al, 2009). After deglycosylation, cell lysates were subjected to
Western blotting analysis using anti-HA primary antibody
(1:2,000; Sigma-Aldrich, Saint Louis, MO, USA) and rabbit anti-
mouse HRP-conjugated secondary antibody (1:20,000, Invitrogen).
Total protein abundance was calculated from the PNGase F-
treated samples (~120 kDa), and the maturity index was calcu-
lated as the fraction of the mature (i.e. EndoH-resistant band,
140-kDa) to the total protein using the ImageJ program (Wayne
Rasband, NIH, USA). Three independent experiments were
performed in quadruplicate.
Cell surface antibody binding assay
COS7 cells were transiently transfected with N-terminus flag-
tagged KLB constructs and analyzed for KLB expression on the
cell surface using an anti-flag antibody (1:1,500) and [125I]-
rabbit anti-mouse IgG (300,000 cpm/well; Perkin Elmer,
Waltham, MA, USA) as previously reported (Raivio et al, 2009).
Samples were run in quadruplicate and the experiment repeated
three times.
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Caenorhabditis elegans studies
Caenorhabditis elegans strains were maintained at 20°C as described
(Brenner, 1974). The single mutant alleles klo-2 (ok1862; Polanska
et al, 2011) and klo-1 (ok2925) were generated by the C. elegans
Knockout Consortium, and strains carrying these alleles were
obtained from the Caenorhabditis Genetics Centre (CGC), and back-
crossed at least three to five times prior to analysis. Both alleles are
presumed null. TC446 is a double mutant of ok1862 and ok2925 and
was generated by standard genetic crossing.
The huKLB constructs were derived from the plasmids pTK37
(pklo-1::gfp) and pTK53 (pklo-2::gfp; Polanska et al, 2011).
Sequences encoding for wild-type human KLB and the F777del vari-
ant cDNAs were cloned downstream of klo-1 and klo-2 promoter
sequences, removing sequences encoding for GFP present in the
original plasmids pTK37 and pTK53, but retaining the unc-54
3’UTR. Since both promoters gave similar results, the rest of the
mutant human KLB cDNAs were cloned similarly downstream of
the klo-1 promoter in pTK37. All DNA constructs were confirmed by
sequencing. Transgenic arrays were generated using standard germ
line transformation techniques (Mello et al, 1991). DNA constructs
were injected to klo-2 (ok1862); klo-1 (ok2925) double mutant
C. elegans, at 20 ng/ll with Ptph-1::mCherry at 40 ng/ll as injec-
tion marker and pBluescript. Two to five independent transgenic
lines were analyzed for each DNA construct. Fluorescent and DIC
images were acquired using Zeiss AxioCam MRm camera mounted
on Zeiss Axioskop2 or Zeiss Axioimager Z1 microscopes equipped
with epifluorescence and DIC optics. Images were captured using
Axiovision/Zen and further cropped and scaled using Adobe Photo-
shop CS4.
Mouse studies
Housing
The generation and genotyping of KlbKO mice, kindly provided by
Prof. Nabeshima, was previously described (Ito et al, 2005), and all
animals used in this study were backcrossed onto a pure C57BL/6J
background for more than 10 generations. KlbKO mice were
obtained from heterozygous breeding pairs, and KlbHET mice were
obtained from heterozygous wild-type breeding pairs. After weaning
at 21 days of age, all mice were housed at room temperature (22°C)
with a 12-h-light/12-h-dark cycle and free access to water and food.
Reproductive assessment
To assess puberty, post-weaning female mice were inspected daily
to measure body weight and determine vaginal opening. Day of first
estrus was determined after vaginal opening by daily cytological
analysis of vaginal smears under an inverted microscope.
To study reproductive capacity, estrous cyclicity was monitored
in 3-month-old females for 4 consecutive weeks by daily cytological
analysis of vaginal smears. Blood samples were collected at different
estrous cycle stages for LH measurement. To study fertility, a
continuous mating protocol was used to measure the number of
litters per females and litter size on KlbKO and WT littermates
housed in a cage with a confirmed fertile WT male for 7 months.
The reproductive capacity of KlbHET mice was assessed by a short-
term fertility test. Briefly, WT and KlbHET females housed together
(1:1) were exposed to a confirmed fertile male for 2 nights. To
induce proestrus with a preovulatory LH surge, KlbKO and WT
females were exposed to bedding enriched with sexually experi-
enced male urine, and sacrificed the evening of the third day of
exposure. Blood was collected by intracardiac puncture and immedi-
ately placed on ice until plasma separation, and then stored at
80°C until LH measurement by ELISA.
Females underwent GnRH and Kisspeptin testings on the day of
first diestrus, and blood samples were collected before and after IP
injection of either 0.25 lg GnRH or 1 nmole Kisspeptin (Kp-10) per
mouse. Briefly, 4 ll blood was collected by tail puncture, diluted in
PBS Tween 0.05%, immediately frozen on dry ice, and stored at
80°C until LH measurements by ELISA.
To assess ovarian morphology, ovaries from 3- to 6-month-old
KlbKO and WT littermates were collected and weighed, fixed by
immersion in 4% paraformaldehyde (PFA) solution and stored at
4°C until tissue processing. Paraffin-embedded ovaries were serially
sectioned at 5 lm thickness and stained with hematoxylin–eosin
(histology facility, University of Lausanne, Vaud, Switzerland).
Fresh and regressing corpora lutea were counted in every 5th section
of an ovary by comparing the section with the preceding and follow-
ing sections.
Metabolic assessment
Food intake was measured for mice placed in individual cages during
at least 3 consecutive days. Lean mass, fat mass, and percent fat were
determined on awake mice using an Echo MRI analyzer (Whole Body
Composition Analyzer, Echo medical systems, Houston, TX, USA).
Females underwent a glucose tolerance test (GTT) after an overnight
fast. Glucose (2 mg/g b.w.) was administered intraperitoneally, and
glucose levels were determined in tail blood using an ACCU-CHEK
Aviva blood glucose monitor and appropriate test strip (Roche Diag-
nostics). Oxygen consumption (VO2), carbon dioxide production
(VCO2), and spontaneous locomotor activity were determined using
indirect, open-circuit calorimetry in an Oxymax Metabolic Chamber
system (Columbus Instruments, Columbus, OH, USA). The mice
(with free access to food and water) were housed in separate cham-
bers for 48 h for acclimatization before starting 48 h measurements.
The average VO2 was calculated during 48 h—two light cycles and
two dark cycles (Somm et al, 2005, 2014).
Biochemical studies
Plasma total, HDL-, and LDL-cholesterol levels were analyzed using
the Cobas C111 automated platform (Roche Diagnostics). Plasma
insulin and leptin were measured with the metabolic Milliplex kit
(MADKMAG-71K, Merck Millipore). LH was measured with an in-
house, sensitive, two-site sandwich immunoassay as previously
described (Steyn et al, 2013).
GnRH neuron neuroanatomical analysis
Brains were obtained from adult females by decapitation
under deep general anesthesia (100 mg/kg of ketamine HCl and
10 mg/kg xylazine HCl) and preserved as previously described
(Messina et al, 2011). Coronal hypothalamic sections were
immunofluorescently stained for GnRH neurons using rabbit
anti-GnRH (1:1,000; Immunostar) as primary antibody following
a previously reported protocol (Messina et al, 2011). Confocal
immunofluorescent imaging was performed using an inverted
microscope (Zeiss LSM 780 Quasar), and images were processed
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using ImageJ and Adobe Photoshop CS5. All slides were coded to
blind sample identification prior to analysis of GnRH neurons
number and distribution. Neurons were manually counted in each
section along the rostro-caudal axis from the medial septum to
the ME. For quantification of GnRH neuron distribution, serial
sections were aligned at the OVLT as a common anatomical land-
mark between samples.
Gene expression analysis
Brain tissues were micro-dissected on a standard stereo-microscope
under RNase-free conditions. Total RNA from tissues and cell
cultures was extracted using TRIzol reagent (Invitrogen). Standard
protocols were followed for quantifying gene expression. Primers for
detecting Hprt, Rps29, Klb, Fgfr1, Gnrh1, Lepr, Kiss1r, Kiss1, Pomc,
Avp, and Npy are available in Appendix Table S2. GnRH neurons
were isolated by fluorescence-activated cell sorting (FACS) from
adult GnRH::GFP transgenic mice and gene expression performed as
previously reported (Messina et al, 2016) using exon-boundary-
specific TaqMan Gene Expression Assays (Applied Biosystems):
Gnrh1 (Gnrh1-Mm01315605_m1), Klb (Klb-Mm00473122_m1).
Control housekeeping genes: r18S (18S-Hs99999901_s1); Actb
(Actb-Mm00607939_s1).
Median eminence explant cultures and GnRH secretion determination
Adult female mice were sacrificed on the day of diestrus and ME
explants were dissected and processed as previously described
(Prevot et al, 1999). Conditioned medium was collected after
explants were treated with increasing doses of rFGF21 (20 min) or
with KCl 0.05 M in order to induce the release of the entire GnRH
vesicle pool. Collected media were analyzed for GnRH content
following a GnRH ELISA protocol (Phoenix Pharmaceuticals Inc.,
California, Catalog no. #FEK-040-02).
Immortalized GnRH neuron culture and neurite outgrowth assay
Gn11 and GT1-7 cells (Mellon et al, 1990) were cultured as previously
described (Messina et al, 2011). For neurite outgrowth assay, GT1-7
cells were plated at low density (2.5 × 104 cells/cm2) on poly-L-
lysine-coated 24-well culture plates and treated after adhesion with
rFGF21. After 48 h, cells were fixed for 10 min in 4% PFA and stained
with Coomassie brilliant blue prior to image acquisition. Neurite trac-
ing was performed following recommended procedures using the
ImageJ plugin, NeuronJ (Meijering et al, 2004; Meijering, 2010).
Peripheral injections of fluorescent FGF-21
Five nanomoles of fluorescent rFGF-21 (Cisbio Bioassays) were
injected into the jugular vein of anesthetized Gnrh::gfp mice. Mice
were decapitated 1 min after the injection, and the brain immersion
fixed in 4% PFA (0.1 M PBS pH 7.4) for 2 h then placed in the same
fixative + 20% sucrose overnight at 4°C. Brains were frozen in
liquid nitrogen-cooled isopentane, and 30-micrometer-thick cryostat
sections were collected on superfrost glass slides. Blood vessel stain-
ing was performed using rabbit anti-laminin antibody (Sigma
AB19012, 1:100).
The mice experimental protocols were performed in accordance
with the Swiss animal welfare laws under the authorization of the
Service de la consummation et des affaires ve´te´rinaire Vaud (no. VD
2659) and with the approval of Institutional Ethics Committees for the
Care and Use of Experimental Animals of the Universities of Lille.
Statistical analysis
For in vitro and in vivo experiments, sample sizes were chosen
according to the standard practice in the field. Unless otherwise
indicated, all analyses were performed using Prism 7 (GraphPad
Software), assessed for normality and variance, and log-trans-
formed when appropriate. The analysis of differences between
the allele frequency of KLB mutations in CHH patients and ExAC
controls was performed by Fisher’s exact test. For in vitro
reporter gene assays, the activity of each FGFR1 or KLB mutant
was compared to WT in terms of EC50 dose and the maximal
FGF response by F-test. Expression levels of WT and KLB
mutants were compared using an unpaired t-test. In the
C. elegans assay, a two-tailed Fisher’s exact test was used to
determine significance between human KLB WT vs. mutants
rescue. For comparison of multiple groups with one or two inde-
pendent variables, statistical significance was determined using
one- or two-way ANOVA followed by Fisher’s least significant
difference post hoc analysis or Sidak’s multiple comparisons test.
For comparison between two groups of normally distributed data,
a paired or unpaired t-test was used when appropriate. For
comparison of event/time curves (i.e. timing of puberty), the
Gehan–Breslow–Wilcoxon test was used. Pregnancy frequencies
from the short-term fertility test were compared using chi-squared
test. Unless otherwise indicated, the significance level was set at
P < 0.05. Data groups are indicated as mean  SEM. The exact
P-values of each analysis are listed in Appendix Table S3.
Expanded View for this article is available online.
The paper explained
Problem
Reproduction is regulated by the hypothalamic secretion of gonado-
tropin-releasing hormone (GnRH). Absence of GnRH secretion or
action results in congenital hypogonadotropic hypogonadism (CHH), a
rare genetic disorder characterized by lack of puberty and infertility.
Multiple causative genes have been identified for CHH including
fibroblast growth factor receptor 1 (FGFR1). FGF21 signals through a
receptor complex comprised of FGFR1 and b-Klotho (encoded by KLB)
and acts as a potent regulator of metabolism. Given the close associa-
tion between energy balance and reproductive fitness, we hypothesize
that FGF21/KLB/FGFR1 signaling is implicated in GnRH biology and
that mutations in FGF21/KLB/FGFR1 gene network underlie CHH.
Results
Combining human genetics, mouse models, and molecular biology, we
identified that 13 of 334 (4%) of CHH probands harbor a heterozygous
loss-of-function mutation in KLB. No mutations were identified in
FGF21. The majority of CHH probands with KLB mutations exhibit
metabolic defects. Mice deficient in Klb have delayed sexual matura-
tion and impaired fertility due to a hypothalamic defect. FGF21
enhances GnRH release in vitro. Peripheral FGF21 have a potential to
reach the hypothalamic GnRH neuron terminals residing outside of
the blood–brain barrier.
Impact
We demonstrate that FGF21/KLB/FGFR1 signaling plays an essential
role in GnRH biology and is a novel link between metabolism and
reproduction in humans.
ª 2017 The Authors EMBO Molecular Medicine
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